

ClinBroD : Clinical Investigation network in Bronchial Diseases

Network Aims:

- To **strengthen** French clinical research in bronchial diseases.
- To **promote** partnership between industrial sponsors and public research centers for clinical trials.
- To **exceed** patient enrollment targets.

Network human resources:

33 investigators
14 study nurses
22 study coordinators

High-performance technical equipment:

10 Spirometers
11 Plethysmographs
10 exhaled NO analyzers
7 TLCO analyzers
6 VO₂ analyzers

Conditions of ClinBroD membership:


- To have an **expertise** in industrial clinical trials in the field of bronchial diseases (asthma, COPD, cystic fibrosis).
- To have physicians involved in clinical research as well as study coordinators and study nurses dedicated to clinical trials.

Up to date, 9 centers are participating in ClinBroD whereas 7 centers participated when the network was created.

Network Members:

ClinBroD associates : four Clinical Investigational Centers (CIC), two private institutions and three non profit organizations.

- CIC 0005 Inserm - CHU de Bordeaux, Dr P.O. Girodet
- CIC 0004 - Equipe Thorax - CHU de Nantes, Pr. A. Magnan
- CIC07 Inserm - CHU Paris Bichat, Pr. M. Aubier
- CIC Lille, Pr. I. Tillie-Leblond
- Groupe de Recherche en Allergologie (Strasbourg), Pr. F. de Blay
- Allerpneumassilia (Marseille), Pr. P. Chanez
- MED BIO MED (Montpellier), Dr. A. Bourdin
- Service de Pneumologie et Réanimation Respiratoire (Clamart), Pr. M. Humbert
- Service de Pneumologie CHR Réunion (Saint Pierre), Dr. F. Paganin



Bronchial diseases such as asthma, chronic obstructive pulmonary disease (COPD) or cystic fibrosis are major issues in public healthcare.

- Asthma prevalence ranges from 5 to 20 % of the population depending on the country, and mainly affects young subjects. The incidence is increasing in Europe. 10 % of asthmatic patients suffer from severe asthma which is a real problem in terms of therapeutic management.
- COPD prevalence ranges from 4 to 10 % of the population. It is a common disease which incidence increases in Europe. This is currently the 4th cause of death.
- Cystic fibrosis is the most common serious genetic disease in industrialized countries.

Therefore, clinical research in these diseases should be a national and European priority.

In 2009, ClinBroD was launched and leads pharmaceutical industries to reinforce the presence of the French centers in multicentric clinical trials as demonstrated by the increase of new trials in 2010 and 2011.

Network organization:

Coordination meetings twice a year.
Regular e-mail contacts and teleconferences between centers

2010 Activity:

282 patients enrolled in phase II and III industrial trials while the objective was 266 patients in **13 ongoing clinical studies**.

Contacts:

Network coordinator:
Pr. Patrick Berger
Phone: +33 (0)5 57 65 65 13
patrick.berger@chu-bordeaux.fr

Network study coordinator:
Virginie Niel
Phone: +33 (0)5 57 65 60 39
Fax: +33 (0)5 57 62 31 73
virginie.niel@chu-bordeaux.fr

